Adagene Inc

NASDAQ ADAG

Data sourced from

and

Download Data

Adagene Inc Interest Coverage Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending December 31, 2023: 85.13%

Adagene Inc Interest Coverage Ratio 1 year YoY Change (%) is 85.13% for the Trailing 12 Months (TTM) ending December 31, 2023, a 168.49% change year over year. The interest coverage ratio is a measure of a company's ability to meet its interest payment obligations on its outstanding debt. It is calculated by dividing the company's earnings before interest and taxes (EBIT) by its interest expense. This ratio indicates the extent to which a company's earnings can cover its interest expenses. A higher interest coverage ratio suggests that the company has a greater capacity to make interest payments, indicating lower financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Adagene Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -115.02, a -124.29% change year over year.
Adagene Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 473.53, a 483.29% change year over year.
Adagene Inc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -123.55.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends